HK32492A - Drug preparations of reduced toxicity - Google Patents

Drug preparations of reduced toxicity

Info

Publication number
HK32492A
HK32492A HK324/92A HK32492A HK32492A HK 32492 A HK32492 A HK 32492A HK 324/92 A HK324/92 A HK 324/92A HK 32492 A HK32492 A HK 32492A HK 32492 A HK32492 A HK 32492A
Authority
HK
Hong Kong
Prior art keywords
drug
ligand
toxicity
aminoglycoside
amphotericin
Prior art date
Application number
HK324/92A
Other languages
English (en)
French (fr)
Inventor
Andrew Stuart Janoff
Mircea Constantine Popescu
Carl R. Alving
Original Assignee
The Liposome Company, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24419861&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK32492(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Liposome Company, Inc. filed Critical The Liposome Company, Inc.
Publication of HK32492A publication Critical patent/HK32492A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Toxicology (AREA)
  • Botany (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Claims (11)

1. Arzneimittelzubereitung mit verringerter Toxizität, umfassend eine Mischung aus
(a) einem pharmazeutisch wirksamen therapeutischen Arzneimittel, das toxische Wirkungen bei Menschen oder Tieren durch Binden an einen Toxizitätsrezeptor aufweist, wobei das Arzneimittel aus den Aminoglykosid-Antibiotika den Polyenmakrolid-Antibiotika, Adriamycin und Cisplatin gewählt wird, und
(b) einem Liganden, der die Bindung des Arzneimittels zu dem Toxizitätsrezeptor in vivo verhindern kann, während er ermöglicht, daß das Arzneimittel seine pharmazeutische Wirksamkeit beibehält, wobei der Ligand ein Phospholipid ist, wenn das Arzneimittel ein Aminoglykosid-Antibiotikum, ein Adriamycin oder Cisplatin ist, und der Ligand ein Sterol oder ein wasserlösliches Derivat davon ist, wenn das Arzneimittel ein Polyenmakrolid-Antibiotikum ist.
2. Arzneimittelzubereitung mit verringerter Toxizität nach Anspruch 1, umfassend eine Mischung aus
(a) einem Aminoglykosid, das toxische Wirkungen bei Menschen oder Tieren durch Binden an einen Toxizitätsrezeptor aufweist, und
(b) einem Liganden, der die Bindung des Aminoglykosids an den Toxizitätsrezeptor in vivo verhindern kann, während er ermöglicht, daß das Aminoglykosid seine pharmazeutische Wirksamkeit beibehält, wobei das Aminoglykosid in einem Molverhältnis von etwa 1:1 bis etwa 1:3 Aminoglykosid:Ligand vorliegt und der Ligand aus der Gruppe, bestehend aus Lysophosphatidylcholin, Phosphorylcholin, Inosithexaphosphat, Phosphoglycerinsäure, Tripolyphosphat, Phosphorlyserin und Phosphatidylinositbisphosphat gewählt wird.
3. Arzneimittelzubereitung mit verringerter Toxizität nach Anspruch 1, umfassend ein Polyenmakrolid-Antibiotikum und einen Liganden, worin der Ligand ein Sterol oder ein wasserlösliches Derivat davon ist.
4. Arzneimittelzubereitung mit verringerter Toxizität nach einem der Ansprüche 1 bis 3, worin der Ligand in einer Konzentration unterhalb der Konzentration, die zur Bildung von Liposomen benötigt wird, vorliegt.
5. Arzneimittelzubereitung nach Anspruch 4, worin das Antibiotikum Amphotericin B ist.
6. Arzneimittelzubereitung nach Anspruch 5, worin das Molverhältnis von Amphotericin B zu PEG-Cholesterin als Ligand bei 1:1 bis etwa 1:14 beträgt.
7. Arzneimittelzubereitung nach Anspruch 6, worin das Molverhältnis von Amphotericin B 1:1 und gegebenenfalls 1:1,6 ist.
8. Arzneimittelzubereitung nach Anspruch 6, worin das Molverhältnis von Amphotericin B 1:5 und gegebenenfalls 1:5,9 ist.
9. Arzneimittelzubereitung nach den Ansprüchen 4 bis 8, worin das Sterol Cholesterin ist.
10. Arzneimittelzubereitung nach Anspruch 1 oder 2, umfassend ein glykosidisches Anthracyclin-Antibiotikum, das Adriamycin ist, und einen Liganden, der ein Phospholipid ist.
11. Arzneimittelzubereitung nach Anspruch 10, worin das Phospholipid Cardiolipin ist.
HK324/92A 1984-05-02 1992-04-30 Drug preparations of reduced toxicity HK32492A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60450384A 1984-05-02 1984-05-02
PCT/US1984/000855 WO1985005030A1 (en) 1984-05-02 1984-05-31 Drug preparations of reduced toxicity

Publications (1)

Publication Number Publication Date
HK32492A true HK32492A (en) 1992-05-08

Family

ID=24419861

Family Applications (1)

Application Number Title Priority Date Filing Date
HK324/92A HK32492A (en) 1984-05-02 1992-04-30 Drug preparations of reduced toxicity

Country Status (11)

Country Link
EP (1) EP0180581B2 (de)
JP (1) JP2506323B2 (de)
AT (1) ATE65912T1 (de)
AU (1) AU3063884A (de)
DE (1) DE3484904D1 (de)
DK (1) DK607885A (de)
FI (1) FI860018A0 (de)
HK (1) HK32492A (de)
PT (1) PT78628B (de)
SG (1) SG18792G (de)
WO (1) WO1985005030A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5409704A (en) * 1985-06-26 1995-04-25 The Liposome Company, Inc. Liposomes comprising aminoglycoside phosphates and methods of production and use
IE60901B1 (en) * 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
US5043107A (en) * 1986-08-21 1991-08-27 Vestar Research, Inc. Preparation small unilamellar vesicles including polyene antifungal antibiotics
US4822777A (en) * 1987-02-27 1989-04-18 Liposome Technology, Inc. Amphotericin B/cholesterol sulfate composition
US5616334A (en) * 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
US6406713B1 (en) 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
AU598958B2 (en) * 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
US4946683A (en) * 1987-11-18 1990-08-07 Vestar, Inc. Multiple step entrapment/loading procedure for preparing lipophilic drug-containing liposomes
CA2044663A1 (en) * 1990-07-12 1992-01-13 Makoto Tanaka Water-dispersible polyene antifungal complexes
PT100486B (pt) * 1992-05-14 1999-07-30 Ineti Inst Nac Engenh E Tecnol Aminoglucosidos lipossomais com altas eficacia de encapsulacao e actividade terapeutica, nomeadamente a netilmicina, e processo para a sua preparcao
JP2915296B2 (ja) * 1993-08-30 1999-07-05 宇野 潤 抗真菌製剤
WO1999027940A1 (en) * 1997-12-01 1999-06-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Formulations for topical treatment of skin infections
CA2450949C (en) 2001-06-28 2009-04-28 John Samuel Methods and compositions for polyene antibiotics with reduced toxicity
CN104856931B (zh) * 2014-02-24 2019-06-18 石药集团中奇制药技术（石家庄）有限公司 一种两性霉素b纳米复合物及其制备方法
CN116473985B (zh) * 2023-03-29 2024-12-10 暨南大学 一种多烯类抗真菌药物组合物及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR19072A (tr) * 1973-11-26 1978-05-01 Pepro Fosforlu tuerevler ihtiva eden fungisid terkipler
US4119724A (en) * 1973-11-26 1978-10-10 Pepro Fungicidal compositions containing phosphorous acid and derivatives thereof
US3993754A (en) * 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
US4160827A (en) * 1978-02-06 1979-07-10 The Upjohn Company Metronidazole phosphate and salts
US4263428A (en) * 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IL55431A (en) * 1978-08-24 1982-07-30 Yeda Res & Dev Anthracycline type antibiotics,their preparation and pharmaceutical compositions comprising them
DE2856333C2 (de) * 1978-12-27 1983-09-22 A. Nattermann & Cie GmbH, 5000 Köln Oral einnehmbare Arzneimittel mit entzündungshemmender Wirkung
US4272525A (en) * 1978-10-23 1981-06-09 Schering Corporation Derivatives of polyene macrolide antibiotics containing an amino sugar moiety, process for the preparation thereof, and pharmaceutical compositions containing them
GR73668B (de) * 1978-11-21 1984-03-28 Hoffmann La Roche
GB2046092B (en) * 1979-03-05 1983-11-02 Toyama Chemical Co Ltd Pharmaceutical composition containing a lysophospholid and a phospholipid
US4291027A (en) * 1979-03-07 1981-09-22 Engelhard Minerals & Chemicals Corp. Method for treating tumors with ethylenediamine platinum (II) and 1,2-diaminocyclohexane-platinum (II) pyrophosphate complexes
US4287187A (en) * 1979-03-07 1981-09-01 Engelhard Minerals & Chemicals Corporation Method for treating tumors with cis-diammineplatinum(II) orthophosphate complexes
US4291023A (en) * 1979-03-07 1981-09-22 Engelhard Minerals & Chemicals Corp. Method for treating tumors using cis-diammineplatinum (II) organophosphate complexes
DE2914789A1 (de) * 1979-04-11 1980-10-16 Nattermann A & Cie Injizierbare arzneimittel mit entzuendungshemmender wirkung
CA1173360A (en) * 1979-06-22 1984-08-28 Jurg Schrank Pharmaceutical preparations
DE2941384A1 (de) * 1979-10-12 1981-04-23 Bayer Ag, 5090 Leverkusen Phosphono-hydroxy-essigsaeure, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE2952115C2 (de) * 1979-12-22 1982-05-06 A. Nattermann & Cie GmbH, 5000 Köln Rosmarinsäure-Phospholipid-Komplex
HU184141B (en) * 1979-12-27 1984-07-30 Human Oltoanyagtermelo Adjuvant particles compositions containing said particles and biologically active substances adsorbed thereon and a process for the preparation thereof
US4430330A (en) * 1980-02-29 1984-02-07 Massachusetts Institute Of Technology Process and composition for treating disorders by administering a phenothiazine and choline
US4346084A (en) * 1980-02-29 1982-08-24 Massachusetts Institute Of Technology Process and composition for treating disorders by administering lithium and choline
JPS5793909A (en) * 1980-12-03 1982-06-11 Sankyo Co Ltd Carcinostatic pharmaceutical having directivity to specific internal organ and its preparation
US4419348A (en) * 1981-04-27 1983-12-06 Georgetown University Anthracycline glycoside compositions, their use and preparation
US4397846A (en) * 1981-05-15 1983-08-09 Murray Weiner Storage-stable lipid vesicles and method of preparation

Also Published As

Publication number Publication date
AU3063884A (en) 1985-11-28
DK607885D0 (da) 1985-12-30
PT78628B (en) 1986-06-18
SG18792G (en) 1992-04-16
FI860018A7 (fi) 1986-01-02
FI860018A0 (fi) 1986-01-02
EP0180581A4 (de) 1988-04-27
DE3484904D1 (de) 1991-09-12
EP0180581A1 (de) 1986-05-14
JPS61502055A (ja) 1986-09-18
EP0180581B2 (de) 1995-12-20
WO1985005030A1 (en) 1985-11-21
ATE65912T1 (de) 1991-08-15
PT78628A (en) 1984-06-01
EP0180581B1 (de) 1991-08-07
JP2506323B2 (ja) 1996-06-12
DK607885A (da) 1985-12-30

Similar Documents

Publication Publication Date Title
US5059591A (en) Drug preparations of reduced toxicity
US4897384A (en) Drug preparations of reduced toxicity
EP0180581B1 (de) Arzneimittelzusammensetzungen ermässigter toxizität
EP0260811B1 (de) Phospholipidpartikeln mit eingeschlossenen Polyen-Antibiotika zur Behandlung von systemischen Pilzinfektionen
US4663167A (en) Composition and method for treatment of disseminated fungal infections in mammals
EP0077377B1 (de) Anticyclinglukosidzusammensetzungen, deren verwendung und herstellung
US4978654A (en) Composition and method for treatment of disseminated fungal infections in mammals
US5776912A (en) Lipophilic oligosaccharide antibiotic compositions
US20120202761A1 (en) Compositions and methods of improving the tolerability of daunorubicin when given as orotate salt
EP0213523B1 (de) Pharmazeutische Zusammensetzungen mit acylierten Phospholipiden
Schwendener et al. Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy
CA2123780A1 (en) Amphotericin b composition with enhanced antifungal activity
US4343799A (en) Use of derivatives of 6α-methylprednisolone for the prevention or reduction of adriamycin-induced cardiotoxicity
EP0178911B1 (de) Zusammensetzung mit Gehalt an einem Penem- oder Carbapenemantibiotikum
TWI462743B (zh) 使用4-電子己醣氧化酶生物合成新穎化合物之結構及機制基礎
US5043107A (en) Preparation small unilamellar vesicles including polyene antifungal antibiotics
WO1993023015A1 (en) Liposomal aminoglycoside compositions and process for their preparation
Fountain DRUG PREPARATIONS OF REDUCED TOXCITY 75 Inventors
AU739033B2 (en) 13-deoxyanthracycline derivatives and processes for preparing them
AU6147794A (en) Use of low density lipoprotein with cytotoxic substances
Law et al. Selective inhibition of cardiac cyclic nucleotide phosphodiesterases by doxorubicin and daunorubicin
TW200405814A (en) Method of treating multiple sclerosis
EA005308B1 (ru) Препараты эстрамустинфосфата для парентерального применения
Schindler Immunological effects of amphotericin B desoxycholate and liposomal amphotericin B on splenocytes from immune-normal and immune-compromised mice

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20040530

PE Patent expired